Attached Carole Ho - 10 Aug 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
10 Aug 2023
Net transactions value
-$68,997
Form type
4
Filing time
14 Aug 2023, 17:12:32 UTC
Previous filing
08 Jun 2023
Next filing
16 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $68,997 -2,857 -1.5% $24.15 185,577 10 Aug 2023 See footnote F1, F2, F3, F4
holding DNLI Common Stock 25,000 10 Aug 2023 See footnote F5
holding DNLI Common Stock 114,124 10 Aug 2023 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.99 to $24.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5,625 RSUs held by the Reporting Person.
F4 The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F5 The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
F6 Includes 113,714 RSUs.